Moderna Inc

MRNA

NASDAQ. Currency in USD

181.48 +5.57 ( +3.17% )

Real time prices: December 01

Market Cap.
69.72B
Beta (5Y monthly)
1.73
Price/Earnings
6.38
EPS (TTM)
27.64
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
4.87M
1y Target Est.
209.47
Day's Range
172.38
-
185.90
52 Week's Range
115.03
-
321.31

Historical Summary

Performance
EPS growth
Share Buybacks

About Moderna Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.modernatx.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
405.45M
Employees
3700
Address
200 Technology Square, Cambridge, MA, United States, 02139
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Latest news

China’s zero-COVID strategy makes no sense and its homegrown vaccines are not ‘particularly effective,’ says  Fauci
China’s zero-COVID strategy makes no sense and its homegrown vaccines are not ‘particularly effective,’ says Fauci

Widespread protests across China over the government's zero-COVID policy dominated headlines on the pandemic on...
By MarketWatch - 3 days ago

China's zero COVID strategy 'doesn't make public health sense,' says Fauci
China's zero COVID strategy 'doesn't make public health sense,' says Fauci

President Joe Biden's chief medical adviser, Dr. Anthony Fauci, says China's COVID-19 strategy of lockdowns...
By MarketWatch - 4 days ago

Is Novavax Stock a Buy Now?
Is Novavax Stock a Buy Now?

There's probably not much good news coming for this biotech in the near future.
By The Motley Fool - 5 days ago

The Worst Mistake Moderna Investors Can Make in 2023
The Worst Mistake Moderna Investors Can Make in 2023

Moderna faces a major transition in 2023.
By The Motley Fool - 5 days ago

Confused about COVID boosters? Here’s what the science and the experts say about the new generation of shots.
Confused about COVID boosters? Here’s what the science and the experts say about the new generation of shots.

Less than 11% of Americans have opted to get the bivalent COVID-19 booster shot ahead...
By MarketWatch - 1 week ago

Novavax Stock: Buy, Sell, or Hold in 2023?
Novavax Stock: Buy, Sell, or Hold in 2023?

The shares are heading for almost a 90% loss this year.
By The Motley Fool - 1 week ago

Novavax (NVAX) Cancels COVID Jab Supply Deal With GAVI
Novavax (NVAX) Cancels COVID Jab Supply Deal With GAVI

Novavax (NVAX) claims that GAVI's failure to procure its COVID vaccine doses is a reason...
By Zacks Investment Research - 1 week ago

Confused about COVID boosters? Here’s what the science and the experts say about the new generation of shots.
Confused about COVID boosters? Here’s what the science and the experts say about the new generation of shots.

Less than 11% of Americans have opted to get the bivalent COVID-19 booster shot ahead...
By MarketWatch - 1 week ago